Thrombocytopenia

7 trials 4 recruiting MedDRA PT
7 Registered trials
4 Recruiting
6 Unique sponsors
5 Unique IMPs
7 Commercial trials
Drug classes (ATC)
B Haematology (ATC B) 3
— ATC code not specified 3
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Kinase inhibitor 1 substance
Colony-stimulating factor 1 substance
Immunoglobulin 1 substance
Phase III: 3 Phase II: 1 Other: 3

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

3 trials
  • Amgen Inc. Commercial
    ROMIPLOSTIM
    2023-507149-27-00 5 countries 2019 n=46
    Recruiting
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd. Commercial
    RAFUTROMBOPAG ETHANOLAMINE
    2025-524209-34-00 5 countries 2026 n=58
    Recruiting
  • Kedrion S.p.A. Commercial
    HUMAN NORMAL IMMUNOGLOBULIN (IV)
    2023-507115-35-00 5 countries 2025 n=24
    Recruiting

Phase II

1 trial
  • Karyopharm Therapeutics Inc. Commercial
    RUXOLITINIB
    2024-511309-47-00 13 countries 2024 n=38
    Recruiting

Other

3 trials
  • Bluepharma Industria Farmaceutica S.A. Commercial
    ELTROMBOPAG OLAMINE
    2022-502701-15-00 1 country 2023 n=72
    Ended
  • Bluepharma Industria Farmaceutica S.A. Commercial
    ELTROMBOPAG OLAMINE
    2022-502702-32-00 1 country 2023 n=72
    Ended
  • Qilu Pharmaceutical Co. Ltd. Commercial
    IMP not specified
    2025-523355-59-00 1 country n=76
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Bluepharma Industria Farmaceutica S.A. Commercial 2 Other 0
Qilu Pharmaceutical Co. Ltd. Commercial 1 Other 0
Karyopharm Therapeutics Inc. Commercial 1 Phase II 1
Amgen Inc. Commercial 1 Phase III 1
Jiangsu Hengrui Pharmaceuticals Co. Ltd. Commercial 1 Phase III 1
Kedrion S.p.A. Commercial 1 Phase III 1
New trials by year
2019
1
2023
2
2024
1
2025
1
2026
1
← All indication landscapes